A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).

被引：0
作者：
Townsend, A. R.
Pirc, L.
Hardingham, J.
Karapetis, C. S.
Tebbutt, N. C.
Singhal, N.
Price, T. J.
机构：
[1] Queen Elizabeth Hosp, Adelaide, SA, Australia
[2] Basil Hetzel Inst, Adelaide, SA, Australia
[3] Flinders Med Ctr, Adelaide, SA, Australia
[4] Austin Hosp, Ludwig Oncol Unit, Heidelberg, Vic 3084, Australia
[5] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[6] Queen Elizabeth Hosp, Woodville, SA 5011, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS162
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy forMetastatic Colorectal Cancer
    Louvet, C.
    Andre, T.
    Gamelin, E.
    Hebbar, M.
    Mabro, M.
    Bennamoun, M.
    Rassam, H.
    de Gramont, A.
    JOURNAL OF ONCOLOGY, 2010, 2010
  • [42] Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer
    Hejna, M
    Köstler, WJ
    Raderer, M
    Tomek, S
    Brodowicz, T
    Scheithauer, W
    Wiltschke, C
    Zielinski, CC
    ANTI-CANCER DRUGS, 2000, 11 (08) : 629 - 634
  • [43] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Hidekazu Kuramochi
    Masayuki Ando
    Michio Itabashi
    Go Nakajima
    Kazuyuki Kawakami
    Mie Hamano
    Eiichi Hirai
    Hajime Yokomizo
    Ryuji Okuyama
    Tatsuo Araida
    Kazuhiko Yoshimatsu
    Shingo Kameoka
    Kazuhiko Hayashi
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 579 - 585
  • [44] Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer:a single-institution experience
    Mohamed A.Daoud
    Engy M.Aboelnaga
    Wael M.Mohamed
    Cancer Biology & Medicine, 2016, (01) : 136 - 141
  • [45] Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer:a single-institution experience
    Mohamed A.Daoud
    Engy M.Aboelnaga
    Wael M.Mohamed
    Cancer Biology & Medicine, 2016, 13 (01) : 136 - 141
  • [46] A phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab
    Nakajima, Go
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Lino, Takayuki
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER RESEARCH, 2016, 76
  • [47] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Nakajima, Go
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 579 - 585
  • [48] Phase II study of irinotecan plus panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma (EAC)
    Atasoy, A.
    Yoon, H.
    Egloff, A. M.
    Ferris, R. L.
    Zaidi, A. H.
    Hough, B.
    Forastiere, A. A.
    Jobe, B. A.
    Nason, K. S.
    Gibson, M. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience
    Daoud, Mohamed A.
    Aboelnaga, Engy M.
    Mohamed, Wael M.
    CANCER BIOLOGY & MEDICINE, 2016, 13 (01) : 136 - 141
  • [50] Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer
    Fuchs, CS
    Moore, MR
    Harker, G
    Villa, L
    Rinaldi, D
    Hecht, JR
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) : 807 - 814
12345